Epoch Investment Partners Inc. Sells 11,184 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Epoch Investment Partners Inc. cut its holdings in UroGen Pharma Ltd. (NASDAQ:URGN) by 8.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,688 shares of the company’s stock after selling 11,184 shares during the period. Epoch Investment Partners Inc. owned approximately 0.54% of UroGen Pharma worth $1,339,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in shares of UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after acquiring an additional 1,402 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of UroGen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after purchasing an additional 3,024 shares during the period. Legal & General Group Plc lifted its stake in shares of UroGen Pharma by 24.6% in the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after buying an additional 3,920 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of UroGen Pharma during the 4th quarter worth $59,000. Finally, Wells Fargo & Company MN grew its stake in UroGen Pharma by 2.7% in the 4th quarter. Wells Fargo & Company MN now owns 221,540 shares of the company’s stock valued at $2,359,000 after buying an additional 5,801 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of recent analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, March 10th. The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday. HC Wainwright cut their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Scotiabank assumed coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price objective on the stock. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and a consensus price target of $32.86.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

UroGen Pharma Trading Down 6.9 %

Shares of URGN stock opened at $9.67 on Monday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80. UroGen Pharma Ltd. has a 12-month low of $8.94 and a 12-month high of $20.70. The firm has a 50-day moving average price of $10.49 and a 200 day moving average price of $11.17.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. Research analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.